title: Amelioration of hyperglycemia and metabolic syndromes in type 2 diabetic KKA(y) mice by poly(gamma-glutamic acid)oxovanadium(IV) complex.
abstract: Recently, we found that poly(gamma-glutamic acid)oxovanadium(IV) complex (VO(gamma-pga)) exhibits a potent antidiabetic activity in streptozotocin (STZ)-induced type 1 diabetic mice. This result prompted us to examine its ability to treat the type 2 diabetic model KKA(y) mice with insulin resistance. We studied the in vivo antidiabetic activity of VO(gamma-pga), compared with that of vanadium(IV) oxide sulfate (VS) as control. Both compounds were orally administered at doses of 5-10 mg (0.1-0.2 mmol) V kg(-1) body mass to the KKA(y) mice for 30 days. VO(gamma-pga) normalized the hyperglycemia within 21 days, whereas VS lowered the blood glucose concentration only by a small degree. In addition, the glucose intolerance, HbA(1c) level, hyperinsulinemia, hypercholesterolemia, and hyperleptinemia were significantly improved in VO(gamma-pga)-treated KKA(y) mice compared with those treated with VS. Based on these observations, VO(gamma-pga) is proposed to be the first orally active oxovanadium(IV)-polymer complex for the efficacious treatment of not only type 2 diabetes but also metabolic syndrome in animals.
authors.affiliation: Department of Analytical and Bioinorganic Chemistry, Kyoto Pharmaceutical University, 5 Nakauchi-cho, Misasagi, Ymashina-ku, Kyoto 607-8414, Japan.
authors.forename: Subarna
authors.initials: S
authors.lastname: Karmaker
authors.forename: Tapan K
authors.initials: TK
authors.lastname: Saha
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Yoshikawa
authors.forename: Hiromu
authors.initials: H
authors.lastname: Sakurai
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D003921:Diabetes Mellitus, Experimental / Q000150:complications / Q000188:drug therapy*; D005951:Glucose Tolerance Test; D006943:Hyperglycemia / Q000150:complications / Q000188:drug therapy*; D007328:Insulin / Q000097:blood*; D020738:Leptin / Q000502:physiology; D008297:Male; D024821:Metabolic Syndrome / Q000150:complications / Q000188:drug therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D009765:Obesity / Q000188:drug therapy; D011099:Polyglutamic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014638:Vanadates / Q000627:therapeutic use*
chemical_list: D001786:Blood Glucose; D007328:Insulin; D020738:Leptin; C511775:poly(gamma-glutamic acid); D011099:Polyglutamic Acid; D014638:Vanadates